Why did ECX.F stock fall so hard pre-market today?

ECX.F stock dropped **-26.85%** mainly due to thin liquidity and no fresh operational news. The company has limited operations and low average daily volume (**460.00**), which amplifies price moves on modest sell orders.

What are the key support and resistance levels for ECX.F stock?

Key levels: support near the Bollinger lower band **€0.63**, intraday pivot **€1.09**, resistance at **€1.40** and the year high **€1.59**. Use limit orders and watch volume when testing these levels.

What does Meyka AI forecast for ECX.F stock?

Meyka AI's model projects a monthly target of **€0.75** and a quarterly target of **€1.52** for ECX.F stock. These imply a near-term downside and a possible quarterly upside. Forecasts are model projections and not guarantees.

Is ECX.F stock a buy after the drop?

Given negative EPS **-3.15**, weak operations, and low liquidity, the stock is high risk. Meyka AI gives a Grade **B** with Suggestion **HOLD**, so any buy should be small and risk-managed.

DE Stocks

Pre-market: ECX.F down 26.85% on 20 Feb 2026, Epigenomics AG (XETRA) outlook

ByHuzaifa Zahoor February 20, 2026February 20, 2026

ECX.F stock tumbled -26.85% pre-market to €1.09 on 20 Feb 2026 after a thin-volume session that amplified selling pressure. The stock opened at €1.24 and the previous close was €1.49, with a trading volume of 502.00 shares versus an average of 460.00. Epigenomics AG (XETRA, Germany) has no scheduled earnings announcement and limited operations, which raises liquidity and execution risk for traders. We parse the drop, valuation, technical signals and model forecasts to set clear watch levels and risk limits.